AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
Resource
J. Clin. Oncol., 33(15),
Journal
J. Clin. Oncol.
Journal Volume
33
Journal Issue
15
Pages
-
Date Issued
2015
Date
2015
Author(s)
Kim, Dong-Wan
Yang, James Chih-Hsin
Chen, Kan
Cheng, Ziqiang
Yin, Lucy
Martin, Paul David
Yang, Zhenfan
Jiang, Haiyi
Ahn, Myung-Ju
SDGs